A new standard of care for the treatment of chronic HCV infection (Q37862076)

24 August 2017

1 reference

title

A new standard of care for the treatment of chronic HCV infection (English)

1 reference

24 August 2017

Stefan Zeuzem

1 reference

24 August 2017

Wolf Peter Hofmann

1 reference

24 August 2017

language of work or name

English

0 references

publication date

5 April 2011

1 reference

full work available at URL

24 August 2017

https://www.nature.com/articles/nrgastro.2011.49.pdf

file format

Portable Document Format

1 reference

DOI

10.1038/NRGASTRO.2011.49

https://api.crossref.org/works/10.1038/NRGASTRO.2011.49

https://www.nature.com/articles/nrgastro.2011.49

29 November 2024

1 reference

DOI

10.1038/NRGASTRO.2011.49

https://api.crossref.org/works/10.1038/NRGASTRO.2011.49

Nature Reviews Gastroenterology & Hepatology

29 November 2024

published in

1 reference

24 August 2017

1 reference

24 August 2017

1 reference

24 August 2017

page(s)

257-264

1 reference

Hepatitis C virus infection

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

Hepatocellular carcinoma in cirrhosis: incidence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

Peginterferon and ribavirin for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

The hepatitis C virus life cycle as a target for new antiviral therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

The way forward in HCV treatment--finding the right path

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

Treatment predictors of a sustained virologic response in hepatitis B and C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

Interleukin-28B gene polymorphisms do not influence the susceptibility to HIV-infection or CD4 cell decline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

Novel hepatitis C drugs in current trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

Telaprevir for previously treated chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

Resistance to direct antiviral agents in patients with hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

Bile acids modulate glucocorticoid metabolism and the hypothalamic-pituitary-adrenal axis in obstructive jaundice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

Mechanism of action of interferon and ribavirin in treatment of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

Hepatitis C and liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.49

31 March 2020

Identifiers

DOI

10.1038/NRGASTRO.2011.49

1 reference

24 August 2017

1 reference